SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Recruiting · NCT05303519 · Registry updated 2026-08-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), astrocytoma, IDH-mutant, grade 2, astrocytoma, IDH-mutant, grade 3, astrocytoma, IDH-mutant, grade 4, epithelial neoplasm, follicular lymphoma, glioblastoma, glioma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, neuroepithelial neoplasm, oligodendroglioma, primitive neuroectodermal tumor | Recruiting | Phase 3 | 2026-08-28 | NCT05303519 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AnHeart Therapeutics Inc. | 1 |
| Nuvation Bio Inc. | 11 |
61 results · Page 1 of 3
Research sites
Swipe the table sideways for more columns.